Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%

Oral cyclophosphamide vs prednisone or placebo

Complete remission: all renal pathologies · idiopathic steroid‐resistant nephrotic syndrome in children

Oral cyclophosphamide showed no clear difference in complete remission: all renal pathologies compared with prednisone or placebo (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.06 [0.61, 1.87]
2 studies · 84 participants
Low

Oral cyclophosphamide vs prednisone or placebo

Complete remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children

Oral cyclophosphamide showed no clear difference in complete remission: FSGS compared with prednisone or placebo (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.01 [0.43, 2.37]
2 studies · 63 participants
Low

Oral cyclophosphamide vs prednisone or placebo

Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children

Oral cyclophosphamide showed no clear difference in complete or partial remission compared with prednisone or placebo (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.88 [0.53, 1.45]
1 study · 53 participants
Low

Oral cyclophosphamide vs prednisone or placebo

Complete or partial remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children

Oral cyclophosphamide showed no clear difference in complete or partial remission: FSGS compared with prednisone or placebo (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.88 [0.53, 1.45]
1 study · 53 participants
Low

Oral cyclophosphamide vs prednisone or placebo

Treatment failure · idiopathic steroid‐resistant nephrotic syndrome in children

Oral cyclophosphamide showed no clear difference in treatment failure compared with prednisone or placebo (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.59 [0.87, 2.88]
1 study · 60 participants
Low

Oral cyclophosphamide vs prednisone or placebo

Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children

Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.07 [0.19, 5.95]
1 study · 60 participants
Low

Oral cyclophosphamide vs prednisone or placebo

Adverse events: hypertension with seizures · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.71 [0.05, 10.89]
1 study · 60 participants
Very low